[Treatment efficacy of electronic endoscope-guided botulinum toxin injection in adductor spasmodic dysphonia patients].

Objective:To investigate the treatment efficacy of electronic endoscope-Guided botulinum toxin injection in Adductor Spasmodic Dysphonia Patients. Method:Clinical characteristics of forty- three cases were retrospectively analyzed. The disease were diagnosed with adductor spasmodic dysphonia and graded according to the severity of the disease by experienced voice specialist. All the cases were treated by electronic endoscope-guided botulinum toxin type A injection in bilateral thyroarytenoid muscles. All the subjects underwent stroboscopic laryngoscope examination and filled in the Voice Handicap Index-10（VHI-10）. They also filled in the VAS score of Voice related symptoms by self evaluation and other evaluation . One month Later, the patients and someone they lived with filled in the VAS score of Voice related symptoms again. Result:After the first injection, the voice-related symptoms of 35 patients improved to varying degrees..All The average onset time of drug was（2.33±1.86） days. The duration of curative effect ranged from 1 to 6 months, the average duration was（2.42±1.65） months. After injection, no one had serious or persistent adverse reactions. There were significant differences in the total score of VHI-10, physiology（P） and function（F） dimensions in VHI-10 of moderate and severe SD patients before and after injection（P 0.05）, overall evaluation of voice quality and any other subprojects are statistically significant（P 0.05）, overall evaluation of voice quality and any other subitems are statistically significant（P<0.05） in the VAS score of Voice related symptoms. Conclusion:In the absence of LEMG, electronic endoscope-guided botulinum toxin injection in adductor spasmodic dysphonia patients can significantly improve the voice quality and quality of life of adductive SD patients. The method is simple to operate, less traumatic, safe and effective, and easy to carry out outpatients service.